Skip to main content
SpringerLink
Log in

Methylation Profile Landscape in Mesothelioma: Possible Implications in Early Detection, Disease Progression, and Therapeutic Options

  • Protocol
  • First Online:
Cancer Epigenetics

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1238))

Abstract

Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy of the pleura associated with asbestos exposure. Incidence of MPM is expected to increase over the course of next decade in both Europe and the developing countries. Although significant progress has been made in terms of etiology and pathogenesis of this disease, currently available therapeutic options have not significantly improved the survival outcome of patients on standard chemotherapeutic regimens. Integrity of the cellular DNA is often altered in many cancers. Understanding of the molecular mechanisms that regulate cellular DNA alterations to facilitate cancer initiation and development has potential to allow better design of cancer cell inhibitory strategies. In this context, there is a need to explore the gamut of “omics” strategies to provide a comprehensive epigenetics profile for MPM. This chapter discusses the functional genomics and epigenetic patterns observed by various investigators studying MPM patient populations on global fronts, and attempts to present a holistic approach in combating this insidious disease. Here we provide investigators in this field with novel insights and methodologies used in other types of cancers that might have profound impact in the early detection, prognosis and potential therapeutic strategies for MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28:1057–1068

    Article  CAS  PubMed  Google Scholar 

  3. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159

    Article  CAS  PubMed  Google Scholar 

  4. Vandermeers F, Sriramareddy SN, Costa C, Hubaux R, Cosse JP, Willems L (2013) The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 81:311–318

    Article  PubMed  Google Scholar 

  5. Remon J, Lianes P, Martinez S, Velasco M, Querol R, Zanui M (2013) Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev 39:584–591

    Article  CAS  PubMed  Google Scholar 

  6. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591–1603

    Article  CAS  PubMed  Google Scholar 

  7. Jaurand MC (1997) Mechanisms of fiber-induced genotoxicity. Environ Health Perspect 105(Suppl 5):1073–1084

    Article  PubMed Central  PubMed  Google Scholar 

  8. Kelsey KT, Yano E, Liber HL, Little JB (1986) The in vitro genetic effects of fibrous erionite and crocidolite asbestos. Br J Cancer 54:107–114

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Yegles M, Saint-Etienne L, Renier A, Janson X, Jaurand MC (1993) Induction of metaphase and anaphase/telophase abnormalities by asbestos fibers in rat pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 9:186–191

    Article  CAS  PubMed  Google Scholar 

  10. Christensen BC, Godleski JJ, Marsit CJ, Houseman EA, Lopez-Fagundo CY, Longacker JL, Bueno R, Sugarbaker DJ, Nelson HH, Kelsey KT (2008) Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 29:1555–1559

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Bagwe AN, Kay PH, Spagnolo DV (1997) Evidence that DNA methylation imbalance is not involved in the development of malignant mesothelioma. Anticancer Res 17:3341–3343

    CAS  PubMed  Google Scholar 

  12. Christensen BC, Houseman EA, Poage GM, Godleski JJ, Bueno R, Sugarbaker DJ, Wiencke JK, Nelson HH, Marsit CJ, Kelsey KT (2010) Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res 70:5686–5694

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, Karagas MR, Wrensch MR, Yeh RF, Nelson HH, Wiemels JL, Zheng S, Wiencke JK, Bueno R, Sugarbaker DJ, Kelsey KT (2009) Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 69:227–234

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Kohno H, Amatya VJ, Takeshima Y, Kushitani K, Hattori N, Kohno N, Inai K (2010) Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol Rep 24:423–431

    CAS  PubMed  Google Scholar 

  15. Kimura K, Toyooka S, Tsukuda K, Yamamoto H, Suehisa H, Soh J, Otani H, Kubo T, Aoe K, Fujimoto N, Kishimoto T, Sano Y, Pass HI, Date H (2008) The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep 20:1265–1268

    CAS  PubMed  Google Scholar 

  16. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, Naitou M, Doihara H, Kisimoto T, Katayama H, Pass HI, Date H, Shimizu N (2007) Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancer. Int J Cancer 120:566–573

    Article  CAS  PubMed  Google Scholar 

  17. Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, You L, Xu Z, Lin YC, Clément G, Jablons DM (2006) Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 342:1228–1232

    Article  CAS  PubMed  Google Scholar 

  18. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM (2004) Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23:6672–6676

    Article  CAS  PubMed  Google Scholar 

  19. He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM (2005) Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65:743–748

    CAS  PubMed  Google Scholar 

  20. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA (2007) DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 58:220–230

    Article  PubMed Central  PubMed  Google Scholar 

  21. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H (2006) Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54:109–116

    Article  PubMed  Google Scholar 

  22. Destro A, Ceresoli GL, Baryshnikova E, Garassino I, Zucali PA, De Vincenzo F, Bianchi P, Morenghi E, Testori A, Alloisio M, Santoro A, Roncalli M (2008) Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient’s follow-up. Lung Cancer 59:369–376

    Article  PubMed  Google Scholar 

  23. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, Shimokata K, Matsuo K, Hida T, Fujimoto N, Kishimoto T, Issa JP, Sekido Y (2009) Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 69:9073–9082

    Article  CAS  PubMed  Google Scholar 

  24. Kristensen LS, Nielsen HM, Hager H, Hansen LL (2011) Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer 71:130–136

    Article  PubMed  Google Scholar 

  25. Nocchi L, Tomasetti M, Amati M, Neuzil J, Santarelli L, Saccucci F (2011) Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose)polymerase-1-mediated epigenetic mechanism. J Biol Chem 286:19478–19488

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Kosuri KV, Wu X, Wang L, Villalona-Calero MA, Otterson GA (2010) An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun 391:1465–1470

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36:2294–2300

    Article  CAS  PubMed  Google Scholar 

  28. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153

    Article  CAS  PubMed  Google Scholar 

  29. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172

    Article  CAS  PubMed  Google Scholar 

  30. Das PM, Singal R (2004) DNA methylation and cancer. J Clin Oncol 22:4632–4642

    Article  CAS  PubMed  Google Scholar 

  31. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T (2006) Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 66:6080–6086

    Article  CAS  PubMed  Google Scholar 

  32. Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J (2009) Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2:190–206

    Article  CAS  PubMed  Google Scholar 

  33. Kao SC, Reid G, van Zandwijk N, Henderson DW, Klebe S (2011) Molecular biomarkers in malignant mesothelioma: state of the art. Pathology 43:201–212

    Article  CAS  PubMed  Google Scholar 

  34. Wild L, Flanagan JM (1806) Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 2010:50–57

    Google Scholar 

  35. Mund C, Lyko F (2010) Epigenetic cancer therapy: proof of concept and remaining challenges. Bioessays 32:949–957

    Article  CAS  PubMed  Google Scholar 

  36. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, Procopio A, Pelicci PG, Catalano A, Fanelli M (2009) Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 66:184–190

    Article  CAS  PubMed  Google Scholar 

  37. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24–32

    Article  PubMed  Google Scholar 

  38. Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC, Jiang SW (2011) DNA hypermethylation as a chemotherapy target. Cell Signal 23:1082–1093

    Article  CAS  PubMed  Google Scholar 

  39. Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K (2011) Epigenetic modulation enhances the therapeutic effect of anti-IL13R(alpha)2 antibody in human mesothelioma xenografts. Clin Cancer Res 17:2819–2829

    Article  CAS  PubMed  Google Scholar 

  40. Kaelin WG, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell 153:56–69

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Wali A, Pass HI (2005) Genomics and proteomics in mesothelioma. In: Pass HI, Vogelzang NJ, Carbone M (eds) Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies. Springer, New York, pp 186–206

    Chapter  Google Scholar 

  42. Furey ST, Sethupathy P (2013) Genetics driving epigenetics. Science 342:705–706

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Karmanos Cancer Institute, Wayne State University and John D. Dingell VA Medical Center, Detroit, MI, 48201, USA

    Xinbo Zhang, Naimei Tang, Arun K. Rishi & Anil Wali

  2. CRCHD, National Cancer Institute, NIH, Room 6w248, MSC 9746, 9609 Medical Center Drive, Bethesda, MD, 20892-9746, USA

    Anil Wali

  3. Department of Cardiothoracic Surgery, New York University Langone Medical Center, 530 First Avenue, New York, NY, 10016, USA

    Harvey I. Pass

Authors
  1. Xinbo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naimei Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arun K. Rishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harvey I. Pass
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anil Wali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anil Wali .

Editor information

Editors and Affiliations

  1. National Institutes of Health, Rockville, Maryland, USA

    Mukesh Verma

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Zhang, X., Tang, N., Rishi, A.K., Pass, H.I., Wali, A. (2015). Methylation Profile Landscape in Mesothelioma: Possible Implications in Early Detection, Disease Progression, and Therapeutic Options. In: Verma, M. (eds) Cancer Epigenetics. Methods in Molecular Biology, vol 1238. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1804-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1804-1_12

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1803-4

  • Online ISBN: 978-1-4939-1804-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation